Metastatic cSCC Crizotinib Adjuvant BRAFV600-mutant melanoma Gastric bypass Sonic Hedgehog Staging Circulating cell-free DNA Cutaneous squamous cell carcinoma Molecular targeted therapies ALK Surgical excision Antineoplastic agents Resistance ACTH Diagnosis Langerhans cell histiocytosis Anti-PD-1 AZD9291 Osimertinib Allelic imbalance Anti-CTLA-4 Biliopancreatic diversion Bariatric surgery Radiofrequency ablation Merkel cell carcinoma Acute generalized exanthematous pustulosis Follow-up Cemiplimab Oncology BRAF Colorectal carcinoma Biomarker Nivolumab Prevention Radiotherapy Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Prognosis Adjuvant therapy Bisphosphonates Advanced BRAFV600E mutation ALK rearrangement Immunomodulation Histiocytosis Assisted reproductive techniques Survival BRAFV600E Locally advanced Systemic therapy Anti-PD-1 antibody Trametinib Abscopal effect Anti-PD1 Invasive cutaneous squamous cell carcinoma TNM classification Adverse events Immune checkpoint inhibitor Biomarkers Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Chemotherapy Cancer BRAF V600E Androgen insensitivity AML 2-chlorodeoxyadenosine Immunohistochemistry Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Melanoma Non-small cell lung cancer Antibody-drug conjugate Dabrafenib Advanced melanoma BRAF V600-mutation Treatment Children Circulating tumor DNA Immunotherapy Colorectal cancer Wnt Abdominal pain ADN tumoral circulant Adjuvant FOLFOX Polyomavirus Prognostic Plasma Chemoresistance Mesenchymal stromal cells Beta-catenin EGFR Colon cancer Anti-Tumor pharmacology Targeted therapy Cancer bronchique non à petites cellules Liver metastases Anti-PD1 blockade Body mass index Safety Lung adenocarcinoma Metastatic